GlobeNewswire by notified

Champalimaud Foundation partners with Philips to reduce its diagnostic imaging carbon footprint by 50% in five years


March 15, 2023

Lisbon, Portugal and Amsterdam, the NetherlandsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and leading Portuguese translational biomedical research and clinical care provider Champalimaud Foundation, today announced they have signed a strategic partnership aimed at halving the carbon footprint resulting from Champalimaud’s use of diagnostic and interventional imaging equipment by 2028.

The transformation of Champalimaud Foundation’s imaging technology infrastructure will be enabled by a set of practical, scalable measures and innovations, including equipment upgrades, lifetime extensions, process digitalization, circular financing solutions with takeback, and renewable electricity sourcing. It will help drive the quality and efficiency of care delivery, while also realizing more sustainable healthcare. As a result, many more patients are expected to be able to benefit from the hospital’s diagnostic healthcare services.

Global healthcare systems account for 4.4% of global CO₂ emissions [1] – more than aviation or the shipping industry [2]. The cooperation between Champalimaud Foundation and Philips is based on a shared commitment to help mitigate climate change – building on Philips’ acknowledged expertise as a health technology company that is driving systemic change towards more sustainable and equitable patient care through the application of EcoDesign (embedding sustainability into the innovation process), circular economy principles, renewable energy sourcing, and workflow improvement through digitalization.

After conducting a baseline assessment of Champalimaud Foundation’s current CO₂ emissions, Philips will work with the organization to update and renew its diagnostic imaging technology capabilities, keeping it up-to-date with Philips’ latest innovations in diagnostic imaging such as CT and MR systems, while also reducing resource demand, increasing the use of recycled materials, and extending equipment lifespans. As a result, Champalimaud Foundation’s patients and staff will be able to enjoy the outcome benefits of advanced diagnostic imaging coupled with improved patient and staff experiences and more sustainable healthcare delivery.

“The healthcare sector is a significant contributor to CO₂ emissions and therefore has an important role to play in mitigating climate change,” said Leonor Beleza, President of the Champalimaud Foundation. “This partnership will allow us to continue to ensure the best care for our patients while at the same time helping to reduce the healthcare sector’s environmental impact.”

“Alongside improving patient outcomes and increasing efficiency, healthcare providers are increasingly focusing on mitigating their impact on the climate and making more sustainable choices,” said Peter Vullinghs, Market Leader Western Europe for Philips. “We have a strong track record in embedding sustainability in our solutions, our operations, and across our supply chain. Leveraging that deep expertise, we are partnering with the Champalimaud Foundation to make a step-change in their environmental impact, while enabling them to pursue their goal of advancing the prevention, early diagnosis and treatment of cancer.”

Philips will support Champalimaud Foundation’s sustainability targets through a range of health technologies and innovations designed to reduce the foundation’s dependency on natural resources and energy consumption. This includes the installation of Philips Spectral CT 7500 which uses 62.5% less energy [3]. The installation of Philips’ MR helium-free operations’ system, Philips MR – Ingenia Ambition 1.5T that uses a breakthrough design where the magnetic components are completely sealed and only need seven liters of helium over its lifetime compared to roughly 1,500 liters with other Philips’s systems. Additionally, with Philips MR SmartSpeed, the Ingenia Ambition 1.5T uses up to 53% less power per patient scan [4].

Philips will also take back the currently-installed Philips equipment and ensure responsible end-of-use management, to avoid waste going to landfill. In addition, Philip will help the Champalimaud Foundation implement hybrid operating room solutions, providing its specialists with a wide range of image-guided minimally-invasive interventional procedures with enhanced precision and patient safety, resulting in shorter hospitalization compared to traditional surgical interventions. 

[1] Health Care Without Harm (2019). Health care’s climate footprint: How the health sector contributes to the global climate crisis and opportunities for action (p.22). Scope 1 direct emissions originate from the hospitals’ own operations: emissions from the building and transportation. Scope 2 indirect emissions are generated by the production and distribution of energy that is consumed by the hospital. Scope 3 are indirect CO2 emissions caused by the production and transportation of goods and services needed by hospitals such as medicines, food, equipment, clothing and waste treatment.
[3] When compared to an equivalent CT model of one of the industry leaders
[4] Applicable to Ambition S. Philips SmartSpeed power consumption versus Philips SENSE based scanning. Based on COCIR and in-house simulated environment. Results can vary based on site conditions.

For further information, please contact:

Joost Maltha 
Philips Global Press Office 
Tel: +31 6 10 55 8116  

Afonso Vaz Pinto
Champalimaud Foundation
Tel: +34 969 658 256

Raul Araújo
Champalimaud Foundation
Tel: +34 927 414 665

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at

About Champalimaud Foundation:

The Champalimaud Foundation was created in 2004 by the last will and testament of the Portuguese entrepreneur António Champalimaud. It is one of the largest European foundations dedicated to scientific research in the field of Medicine. The Champalimaud Foundation essentially supports research in neurosciences, cancer and vision.
 The mission of the Champalimaud Clinical Center (CCC) is to actively develop advanced research and technological innovation programs, alongside the interdisciplinary delivery of clinical care in the prevention, early diagnosis and treatment of cancer. Its clinical activity is patient-centered, through the personalization of care and promotion of quality of life, providing excellence in care, based on multidisciplinary teams, and providing patients with the opportunity to participate in innovative diagnostic and treatment programs.


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

EgnsINVEST Ejendomme Tyskland A/S - Samlet driftsresultat (EBVAT) i 2022 – 27,1 mio. kr.23.3.2023 13:10:20 CET | pressemeddelelse

Den 23. marts 2023 Samlet resultat før skat i 2022, 15,6 mio. kr.Kreditfaciliteter til rådighed for 35,8 mio. kr.Negativ værdiregulering på 0,68% af investeringsejendommenes dagsværdi (-11,5 mio. kr.) EgnsINVEST Ejendomme Tyskland A/S har realiseret et resultat før skat i 2022 på i alt 15,6, mio. kr. på koncernniveau mod 147,4 mio. kr. sidste år, hvilket ledelsen betragter som tilfredsstillende, da driften af koncernens ejendomme er forbedret siden sidste år. Af årets resultat udgør værdiregulering af investeringsejendommene -11,5 mio. kr. mod 121,1 mio. kr. sidste år. Driftsresultatet (EBVAT) er dermed på 27,1 mio. kr. mod 26,2 mio. kr. sidste år. Årets driftsresultat indfrier de opjusterede forventninger om, at årets EBVAT ville ligge i intervallet 26,8-27,1 mio. kr., hvilket blev meldt ud i den seneste periodemeddelelse. Der er i løbet af året foretaget en tilbageførsel af afsatte hensættelser til tab på erhvervslejere relateret til covid-19. Erhvervslejerne fik under pandemien i 20

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients23.3.2023 12:55:29 CET | Press release

Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy COPENHAGEN, Denmark, March 23, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies today announces that it has developed a new proprietary AI platform technology ObsERV™ to identify a new source of targets for personalized cancer therapy, potentially enabling treatment of patients that are currently considered unresponsive to cancer immunotherapy. ObsERV™, Evaxion’s new proprietary AI platform technology, identifies patient-specific virus targets, so-called ERVs (endogenous retroviruses), expressed in cancer. Evaxion has demonstrated that overexpression of such ERVs is strongly associated with the overall survival of cancer patients,

Auctions of mortgage covered bonds for the refinancing of FlexKort®, RD Cibor6® and RD Euribor3®23.3.2023 12:49:47 CET | Press release

To Nasdaq Copenhagen A/S Executive Board Lersø Parkalle 100 DK-2100 København Ø Telephone +45 7012 5300 23 March 2023 Company Announcement number 22/2023 Auctions of mortgage covered bonds for the refinancing of FlexKort®, RD Cibor6® and RD Euribor3® Realkredit Danmark will hold auctions on SDRO’s for the refinancing of FlexKort®, RD Cibor6® and RD Euribor3® as of 1 July 2023. The auctions will be held on 24 - 25 May 2023. Realkredit Danmark will open two new mortgage covered bonds (SDRO’s) to put on the auctions for the refinancing of RD Cibor6® and RD Euribor3®, respectively. The underlying bond to RD Cibor6® will be used for new loan offers at a later stage whereas the underlying bond to RD Euribor3® will be used for new loan offers immediately after the refinancing has taken place. At the auctions, investors make their bids on the spread to CIBOR 6M and EURIBOR 3M. Regarding FlexKort®, investors make their bids on the price of DK0004626322. The characteristics of the new

Auktioner over obligationer til refinansiering af FlexKort®, RD Cibor6® og RD Euribor3®23.3.2023 12:49:47 CET | pressemeddelelse

Til Nasdaq Copenhagen A/S Direktionen Lersø Parkalle 100 2100 København Ø Telefon 7012 5300 23. marts 2023 Selskabsmeddelelse nummer 22/2023 Auktioner over obligationer til refinansiering af FlexKort®, RD Cibor6® og RD Euribor3® Realkredit Danmark gennemfører auktioner over SDRO til refinansiering af FlexKort®, RD Cibor6® og RD Euribor3® pr. 1. juli 2023. Auktionerne vil blive afholdt den 24. og 25. maj 2023. Til brug for auktionerne åbner Realkredit Danmark to nye obligationer til refinansiering af henholdsvis RD Cibor6® og RD Euribor3®. Obligationen bag RD Cibor6® vil på sigt blive anvendt til lånetilbud mens obligationen bag RD Euribor3® vil blive anvendt til lånetilbud umiddelbart efter refinansieringen. På auktionen skal investorer byde på tillægget til CIBOR 6M og EURIBOR 3M, mens der på auktionen vedrørende FlexKort® skal bydes på kursen til DK0004626322. De nye obligationers karakteristika fremgår af vedlagte bilag. De Endelige vilkår offentliggøres via prospektmeddel

Fixing of coupon rates - Nykredit Realkredit A/S23.3.2023 12:34:03 CET | Press release

To Nasdaq Copenhagen FIXING OF COUPON RATES 23 March 2023 Fixing of coupon rates effective from 27 March 2023 Effective from 27 March 2023, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S will be adjusted. Bonds with quarterly interest rate fixing The new coupon rates will apply from 27 March 2023 to 27 June 2023: Uncapped bonds DK0030486246, (SNP), maturity in 2024, new rate as at 27 March 2023: 3.9900% pa DK0030492053, (SNP), maturity in 2023, new rate as at 27 March 2023: 3.9900% pa DK0030494851, (SNP), maturity in 2023, new rate as at 27 March 2023: 3.7400% pa Questions may be directed toInvestor Relations at investor_relations@nykredit.dkor Rikke Gredsted Seidenfaden, Head of Press Relations,tel +45 44 55 14 49. Attachment Fixing of coupon rates - Nykredit Realkredit - 20230323